Evidence map›Paper›PMID 42181843›Full record

ArticleJournal of clinical and translational hepatology2026

Pegylated Interferon-based Treatment Improves Response Rates in Immune-tolerant Patients with Chronic Hepatitis B: A Prospective Trial.

Min Liu, Lili Zuo, Yuting Zhang, Bing Bu, An Xiao, Ling Zhu, Xiuying Ma, Yilan Wang, Wei Yue, Jiawei Geng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and translational hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Min LiuFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, China.
Lili ZuoDepartment of Infectious Disease and Hepatic Disease, The First People's Hospital of Yunnan Province (The Affiliated Hospital of Kunming University of Science and Technology), Kunming, Yunnan, China.
Yuting ZhangDepartment of Infectious Disease and Hepatic Disease, The First People's Hospital of Yunnan Province (The Affiliated Hospital of Kunming University of Science and Technology), Kunming, Yunnan, China.
Bing BuDepartment of Infectious Disease and Hepatic Disease, The First People's Hospital of Yunnan Province (The Affiliated Hospital of Kunming University of Science and Technology), Kunming, Yunnan, China.
An XiaoDepartment of Infectious Disease and Hepatic Disease, The First People's Hospital of Yunnan Province (The Affiliated Hospital of Kunming University of Science and Technology), Kunming, Yunnan, China.
Ling ZhuDepartment of Infectious Disease and Hepatic Disease, The First People's Hospital of Yunnan Province (The Affiliated Hospital of Kunming University of Science and Technology), Kunming, Yunnan, China.
Xiuying MaDepartment of Infectious Disease and Hepatic Disease, The First People's Hospital of Yunnan Province (The Affiliated Hospital of Kunming University of Science and Technology), Kunming, Yunnan, China.
Yilan WangDepartment of Infectious Disease and Hepatic Disease, The First People's Hospital of Yunnan Province (The Affiliated Hospital of Kunming University of Science and Technology), Kunming, Yunnan, China.
Wei YueDepartment of Infectious Disease and Hepatic Disease, The First People's Hospital of Yunnan Province (The Affiliated Hospital of Kunming University of Science and Technology), Kunming, Yunnan, China.
Jiawei GengDepartment of Infectious Disease and Hepatic Disease, The First People's Hospital of Yunnan Province (The Affiliated Hospital of Kunming University of Science and Technology), Kunming, Yunnan, China.ORCID https://orcid.org/0009-0002-5414-6112
Xueshan XiaFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, China.ORCID https://orcid.org/0009-0001-1177-6387

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: The optimal management strategy for adults with immune-tolerant (IT) chronic hepatitis B infection remains undefined. This study aimed to investigate the efficacy and predictive factors of a pegylated interferon (Peg-IFN)-based treatment strategy in IT patients with chronic HBV infection. Methods: In this pilot, open-label, prospective study, 286 patients aged 18 to 60 years with IT characteristics were enrolled and allocated to one of three groups. The combination group received Peg-IFN for 48-96 weeks, with tenofovir disoproxil fumarate (TDF) initiated at week 12 and continued through week 96 (n = 103). The monotherapy group received TDF monotherapy alone (n = 125), and the control group was monitored without therapeutic intervention (n = 58). Results: No patients in the control group met any predefined efficacy endpoints. Intention-to-treat analysis showed that patients in the combination group achieved significantly higher virological response rates (71.8% vs. 53.6%, Conclusions: A Peg-IFN-based treatment strategy significantly increases response rates compared with TDF monotherapy or observation in patients with IT characteristics.

Indexed as

Antiviral therapyHepatitis B, ChronicImmune tolerancePegylated interferonProspective Studies.Tenofovir disoproxil fumarate

Identifiers

PMID42181843
PMCPMC13195391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.